IDEAYA Biosciences Past Earnings Performance
Past criteria checks 0/6
IDEAYA Biosciences's earnings have been declining at an average annual rate of -33.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 18.1% per year.
Key information
-33.1%
Earnings growth rate
10.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 18.1% |
| Return on equity | -15.1% |
| Net Margin | -4,541.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How IDEAYA Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4 | -178 | 35 | 0 |
| 30 Jun 24 | 12 | -154 | 34 | 0 |
| 31 Mar 24 | 16 | -129 | 30 | 0 |
| 31 Dec 23 | 23 | -113 | 28 | 0 |
| 30 Sep 23 | 23 | -103 | 27 | 0 |
| 30 Jun 23 | 45 | -74 | 26 | 0 |
| 31 Mar 23 | 47 | -68 | 24 | 0 |
| 31 Dec 22 | 51 | -59 | 24 | 0 |
| 30 Sep 22 | 50 | -53 | 23 | 0 |
| 30 Jun 22 | 29 | -66 | 22 | 0 |
| 31 Mar 22 | 32 | -55 | 21 | 0 |
| 31 Dec 21 | 28 | -50 | 20 | 0 |
| 30 Sep 21 | 36 | -37 | 19 | 0 |
| 30 Jun 21 | 36 | -30 | 17 | 0 |
| 31 Mar 21 | 27 | -31 | 17 | 0 |
| 31 Dec 20 | 20 | -34 | 15 | 0 |
| 30 Sep 20 | 9 | -40 | 14 | 0 |
| 30 Jun 20 | 0 | -46 | 13 | -17 |
| 31 Mar 20 | 0 | -44 | 11 | -8 |
| 31 Dec 19 | 0 | -42 | 10 | 0 |
| 30 Sep 19 | 0 | -40 | 9 | 8 |
| 30 Jun 19 | 0 | -42 | 7 | 37 |
| 31 Mar 19 | 0 | -38 | 6 | 35 |
| 31 Dec 18 | 0 | -34 | 5 | 0 |
Quality Earnings: 30J is currently unprofitable.
Growing Profit Margin: 30J is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 30J is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.
Accelerating Growth: Unable to compare 30J's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 30J is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 30J has a negative Return on Equity (-15.09%), as it is currently unprofitable.